SCHEMBL4902435

SCHEMBL4902435

COC(=O)c1cc(S(=O)(=O)NCCSc2nc(-c3ccccc3)cs2)ccc1C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
TP53 P04637 1/20 0.49
MCL1 Q07820 1/20 0.49
PHGDH O43175 5/20 0.48
NPC1 O15118 3/20 0.48
RAB9A P51151 3/20 0.48
HPGD P15428 1/20 0.48
TDP1 Q9NUW8 2/20 0.45
LMNA P02545 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
HTR1A P08908 1/20 0.43
HTR2A P28223 1/20 0.43
HTR7 P34969 1/20 0.43
MAPT P10636 5/20 0.43
ALDH1A1 P00352 3/20 0.43
HSD17B10 Q99714 1/20 0.42
MAPK1 P28482 3/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4906791 0.93 LMNA (0.53) TSHRL3MBTL1TP53MCL1PHGDH
SCHEMBL4901797 0.91 TSHR (0.48) TSHRL3MBTL1TP53MCL1PHGDH
SCHEMBL4905491 0.84 RAB9A (0.45) TSHRL3MBTL1TP53MCL1PHGDH
SCHEMBL4906189 0.81 LMNA (0.45) TSHRL3MBTL1NPC1RAB9AHPGD
SCHEMBL4905936 0.81 SMN1; SMN2 (0.54) TSHRL3MBTL1NPC1RAB9AHPGD
SCHEMBL4902449 0.79 TSHR (0.44) TSHRL3MBTL1TP53MCL1PHGDH
SCHEMBL4906148 0.78 GRK6 (0.48) TSHRTP53HPGDLMNASMN1; SMN2
SCHEMBL4905743 0.76 ALOX5 (0.54) L3MBTL1HPGDLMNASMN1; SMN2MAPT
SCHEMBL4902649 0.75 ALDH1A1 (0.54) TSHRL3MBTL1TDP1LMNAMAPT
SCHEMBL4906166 0.75 MAPT (0.55) TSHRL3MBTL1NPC1RAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080090829-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PFIZER INC. 2008-04-17 US disclosed
US-20080090829-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PFIZER INC. 2008-04-17 US disclosed
US-20080090829-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PFIZER INC. 2008-04-17 US disclosed
US-20060229363-A1 Substituted Heteroaryl- and Phenylsulfamoyl Compounds HAMANAKA ERNEST S 2006-10-12 US disclosed
US-20050288340-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER INC 2005-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229363-A1 Substituted Heteroaryl- and Phenylsulfamoyl Compounds PPARA, PPARG, PPARD TSHR 412/4885L3MBTL1 1234/4885TP53 3260/4885
US-20050288340-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PPARA, PPARG, PPARD TSHR 400/4885L3MBTL1 1246/4885TP53 3421/4885
US-20080090829-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PPARA, PPARG, PPARD TSHR 400/4885L3MBTL1 1246/4885TP53 3421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.